A5001340494- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Organ Donation and Transplantation
- Renal and Vascular Pathologies
- Ferroptosis and cancer prognosis
- Social Media in Health Education
- Pediatric Urology and Nephrology Studies
- Esophageal Cancer Research and Treatment
- Clinical practice guidelines implementation
- Ureteral procedures and complications
- Urologic and reproductive health conditions
- Minimally Invasive Surgical Techniques
- Hormonal and reproductive studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Renal and related cancers
- Patient-Provider Communication in Healthcare
- Molecular Biology Techniques and Applications
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2014-2025
Hospital Clínic de Barcelona
2016-2025
Fundació Clínic per a la Recerca Biomèdica
2025
Universitat de Barcelona
2015-2024
European Association of Urology
2020-2024
Hôpital de la Croix-Rousse
2023
Tampere University Hospital
2022
Universidad Europea
2019
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2014
Puigvert Foundation
2004-2012
Abstract Molecular characterization of radical prostatectomy specimens after systemic therapy may identify a gene expression profile for resistance to therapy. This study assessed tumor cells from patients with prostate cancer participating in phase II neoadjuvant docetaxel and androgen deprivation trial mediators resistance. Transcriptional level 93 genes docetaxel-resistant cell lines microarray was analyzed by TaqMan low-density arrays tumors high-risk localized (36 surgically treated, 28...
Current standard methods used to detect and monitor bladder urothelial cell carcinoma (UCC) are invasive or have low sensitivity. The incorporation into clinical practice of a non-invasive tool for UCC assessment would enormously improve patients' quality life outcome. This study aimed examine the microRNA (miRNA) expression profiles in urines patients order develop accurate reliable diagnose provide information on aggressiveness tumor. We performed global miRNA profiling analysis urinary...
We determined the incidence and characteristic of synchronous upper urinary tract tumors (UUTTs) in patients with primary superficial bladder carcinoma evaluated characteristics related to UUTTs.We performed a retrospective study 1,529 who underwent initial examination excretory urography. Data were analyzed by multivariate analysis using logistic regression. Variables UUTT multiplicity, situ, tumor size, localization bladder, grade stage.A total 28 (1.8%) had simultaneous UUTT. UUTTs showed...
Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer (CRPC). However, most patients eventually develop resistance to this treatment. In study, we aimed identify key molecular genes and networks associated with docetaxel two models of docetaxel-resistant CRPC cell lines test for differentially expressed tumor samples from CRPC. DU-145 PC-3 cells were converted cells, DU-145R PC-3R, respectively. Whole-genome arrays used compare...
Study Type – Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does study add? Prostate growth is ruled by testosterone. Nevertheless, paradigm that high testosterone levels induce prostate cancer development or lead to a poor prognosis in not supported evidence. A growing number studies suggest that, contrary, low are related features such as higher prostate‐specific antigen Gleason score. Our experience shows risk progression those men with lower at their...